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Conclusion 
Despite strong evidence and clinical guidelines 
recommending the use of statins in those with clinical 
evidence of CVD, a large gap exists between guidelines 
and clinical practice in Ireland in this cohort, with only 
68.8% taking statins. In those with diabetes but no CVD 
statin utilisation is lower than expected.  
It is of concern that such a low proportion of those with a 
SCORE risk ≥ 5% are taking statins.  
Previous research identified patient compliance, lack of 
time and Government health policy as factors impeding 
the implementation of CVD prevention guidelines 3. 
Further research is required to examine the future health 
and cost implications of under-treatment in this cohort 
and to identify health system processes which would 
facilitate implementation of the guidelines. Barriers to full 
implementation of the guidelines need to be examined 
and proactive policies pursued to achieve higher levels of 
guideline implementation for both primary and secondary 
CVD prevention. 
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Aim and Objectives 
To examine the extent to which clinical practice in statin 
prescribing adheres to clinical guidelines in those with  
• Existing cardiovascular disease (CVD) 
• Diabetes mellitus (DM) without CVD 
• High or very high SCORE risk 
 
Method 
• Cross-sectional study 
• Irish Longitudinal Study on Ageing (Wave1) 
• Home based interview and health assessment 
• Data collection 2009-2011 
• Representative sample of community living older 
adults in Ireland aged 50 years and older 
• Analysis limited to those aged 50-64 years  
• Self-report of CVD (angina, myocardial infarction, 
bypass surgery, angioplasty or stent, stroke or 
transient ischaemic attack) and diabetes based on 
ever having a doctor’s diagnosis 
• CVD risk in those without CVD or diabetes was 
calculated using the SCORE ‘low’ risk country 
equations 
 
 
Introduction 
The role of statins in the secondary prevention of 
cardiovascular disease (CVD) is well established 1. Statin 
therapy is also recommended as part of the management 
strategy for diabetics 2.  
In asymptomatic individuals, statins are recommended if 
their Systematic Coronary Risk Estimation (SCORE) of 
10 year CVD mortality is high (≥5% and ≤10%) or very 
high (≥10%) and Low-Density Lipoprotein (LDL-C) levels 
are above defined intervention thresholds 2. 
Results 
The response rate to the TILDA survey as a whole was 
62%. In those aged 50-64 years the mean age was 
56.7 years and 45% were male (Table 1). 
 
 
 
 
 
 
Almost 5% (n=167) had established CVD and 4.1% 
(n=141) had diabetes without CVD (Figure 1).  
SCORE risk was estimated in those without established 
CVD or diabetes (n=3077), 40.8% were at low risk, 
54.3% at moderate risk, 4.1% at high risk and 0.6% at 
very high risk of 10 year CVD mortality. In total almost 
5% (n=147) were classified at high or very high risk for 
CVD mortality; this was higher in males compared to 
females (9.6% vs 1.0%) (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
In those whose SCORE risk was high 85% were found to 
have LDL-C levels ≥2.5mmol/L which is the threshold 
for immediate drug intervention. All of those whose 
SCORE risk was very high had LDL-C levels 
≥1.8mmol/L  which is the threshold for intervention in 
this group.  
In total 87% of the combined high and very high SCORE 
risk group met the threshold LDL-C levels for immediate 
drug intervention (Table 2). 
 
 
 
 
 
 
 
 
In those with established CVD 68.8% (95% CI 61.7-
75.9%) were taking statins (Figure 3). In diabetics 
without clinical evidence of CVD only 57.4% (95% CI 
49.1-65.7%) are on statins and in those whose 
SCORE risk was high or very high (≥5%) only 19% 
(95% CI 12.6-25.4%) were found to be taking statins. 
 
 
 
 
 
 
 
 
 
 
In those with established CVD, statin therapy ranged 
from a low of  51.6% in those with a transient 
ischemic attack to 80.3% in those who had 
undergone a revascularization procedure (Table 2). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: High risk groups by statin and total lipid modification therapy  
 
 
Figure 2: SCORE 10 year risk of CVD mortality by sex in those without CVD or Diabetes 
Figure 1: Flow chart of the N of participants included in analysis 
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Table 3: Statin use in those with established CVD (50-64 yrs) 
LDL-C levels mmol/L n 
< 1.8 
n (%) 
1.8 to < 2.5 
n (%) 
2.5 to < 4.0 
n (%) 
4.0 to < 4.0 
n (%) 
>4.9 
n (%) 
CVD 46 
 (27.5) 
56  
(33.5) 
55 
 (32.9) 
5  
(3.0) 
5  
(3.0) 
167 
(100)  
DM (no CVD) 37 
(26.2) 
38 
(26.9) 
48 
(34.0) 
15 
(10.6) 
3 
(2.3) 
141 
(100) 
SCORE 
High 6 
(4.7) 
13 
(10.2) 
75 
(59.0) 
22 
(17.3) 
11 
(8.6) 
127 
(100) 
Very 
high 
0 
(0) 
2 
(10.0) 
9 
(45.0) 
6 
(30.0) 
3 
(15.0) 
20 
(100) 
Table 2: LDL-C levels  in those with  established CVD, diabetes and  SCORE risk ≥5% 
  Males Females Total 
  Mean (SD) Mean (SD) Mean (SD) 
Age  56.6 (4.2) 56.7 (4.2) 56.7 (4.2) 
Sex % 45 55 100 
Current smoker % 18.5 18.5 18.5 
Total Cholesterol  5.0 (1.0) 5.4 (1.0) 5.3 (SD 1.0) 
LDL C (mmol/L) 2.9 (0.9) 3.16 (0.9) 3.0 (SD 0.9) 
HDL C (mmol/L) 1.3 (0.3) 1.7 (0.4) 1.5 (SD 0.4) 
Systolic BP ( mmHg) 137.1 (17.2) 127.6 (17.9) 131.9 (SD 18.3) 
Diastolic BP ( mmHg) 85.3 (10.7) 81.4 (11.0) 83.2 (SD 11.0) 
Table 1: Characteristics of the sample 50-64 years (n=3385) 
